|
End-of-day quote
Taipei Exchange
12/08/2026
|
5-day change | 1st Jan Change | ||
| 33.10 TWD | +0.30% |
|
+3.44% | -5.16% |
Company Valuation: DIVA Laboratories, Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,455 | 1,572 | 2,379 | 2,159 | 2,244 | 2,048 |
| Change | - | 8.06% | 51.31% | -9.25% | 3.94% | -8.76% |
| Enterprise Value (EV) 1 | 1,128 | 1,273 | 2,033 | 1,630 | 1,660 | 1,556 |
| Change | - | 12.91% | 59.64% | -19.84% | 1.86% | -6.24% |
| P/E | 95.4x | 72.4x | 48.3x | 29.4x | 24.1x | 22.7x |
| PBR | 1.47x | 1.59x | 2.34x | 2.09x | 2.13x | 1.99x |
| PEG | - | 1.7x | 0x | 0.6x | 0.9x | -7.22x |
| Capitalization / Revenue | 1.97x | 2.21x | 2.51x | 2.42x | 2.6x | 2.36x |
| EV / Revenue | 1.53x | 1.79x | 2.14x | 1.82x | 1.92x | 1.79x |
| EV / EBITDA | 13.1x | 37.4x | 21.8x | 16.2x | 14x | 14.3x |
| EV / EBIT | 16x | 56.3x | 24x | 17.7x | 14.9x | 15.2x |
| EV / FCF | -23.5x | -47.2x | 51.9x | 6.92x | 16.7x | 1,719x |
| FCF Yield | -4.25% | -2.12% | 1.93% | 14.5% | 5.99% | 0.06% |
| Dividend per Share 2 | 0.26 | 0.37 | 1 | 1.25 | 2 | 2 |
| Rate of return | 1.05% | 1.38% | 2.47% | 3.4% | 5.23% | 5.73% |
| EPS 2 | 0.26 | 0.37 | 0.84 | 1.25 | 1.59 | 1.54 |
| Distribution rate | 100% | 100% | 119% | 100% | 126% | 130% |
| Net sales 1 | 736.9 | 712.2 | 949.2 | 893.8 | 862.3 | 868.8 |
| EBITDA 1 | 86.03 | 34.04 | 93.06 | 100.3 | 118.7 | 109 |
| EBIT 1 | 70.54 | 22.6 | 84.83 | 92.15 | 111.2 | 102.3 |
| Net income 1 | 17.42 | 21.86 | 49.66 | 73.62 | 93.66 | 90.54 |
| Net Debt 1 | -327.1 | -298.9 | -346.1 | -529.4 | -584.2 | -491.1 |
| Reference price 2 | 24.80 | 26.80 | 40.55 | 36.80 | 38.25 | 34.90 |
| Nbr of stocks (in thousands) | 58,668 | 58,668 | 58,668 | 58,668 | 58,668 | 58,668 |
| Announcement Date | 31/03/21 | 28/03/22 | 29/03/23 | 20/03/24 | 13/03/25 | 26/03/26 |
1TWD in Million2TWD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 60.05M | ||
| 61.58x | 7.42x | 25.57x | 0.73% | 137B | ||
| 27.65x | 1.22x | 5.95x | 1.22% | 32.29B | ||
| 14.94x | 1.01x | 5.41x | 3.38% | 15.09B | ||
| 26.23x | 1.25x | 7.93x | 2.77% | 12.41B | ||
| 25.91x | 0.81x | 8.42x | 1.32% | 6.11B | ||
| 13.2x | 4.42x | 11.57x | 3.73% | 5.9B | ||
| 30.02x | 0.61x | 3.13x | -.--% | 3.52B | ||
| Average | 28.50x | 2.39x | 9.71x | 1.88% | 26.56B | |
| Weighted average by Cap. | 48.15x | 5.28x | 18.87x | 1.2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4153 Stock
- Valuation DIVA Laboratories, Ltd.
Select your edition
All financial news and data tailored to specific country editions
















